Skip to main content

Candel Therapeutics, Inc 10-Q for FY2026 Q3

Candel Therapeutics, Inc. (CADL)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 13, 2026

About this 10-Q

Candel Therapeutics, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Candel Therapeutics said aglatimagene achieved a 39% improvement in prostate cancer-specific disease-free survival at 58.0 months median follow-up, plans a BLA submission in the middle of 2027, and paused pancreatic cancer development. AI summary